HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
STRATUS Study: Pomalidomide Is Most Effective Treatment For Refractory Myeloma Patients
Posted: Feb 05, 2015
STRATUS Study: Pomalidomide Is Most Effective Treatment For Refractory Myeloma Patients image

According to results of the STRATUS study, patients with refractory myeloma, oral pomalidomide significantly extends overall and progression-free survival, according to data from the largest study ever conducted in this population. Objective response rates to the regimen, which was well tolerated, were substantial even though the heavily pretreated patients were generally refractory to other novel agents. “These data confirm that pomalidomide plus low-dose dexamethasone is a standard of care for refractory multiple myeloma patients who have failed lenalidomide and bortezomib,” said Meletios A. Dimopoulos, MD, the chairman of the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine, in Greece. He presented the results of the SATRATUS study at the 2014 ASH. For more information on the study and its recommendations, visit Clinical Oncology News and The International Myeloma Foundation.

The author Lizzy Smith

about the author
Lizzy Smith

Lizzy Smith was diagnosed with myeloma in 2012 at age 44. Within days, she left her job, ended her marriage, moved, and entered treatment. "To the extent I'm able, I want to prove that despite life's biggest challenges, it is possible to survive and come out stronger than ever," she says.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Abbvie
Genentech
GSK
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube